Clinical Trial: Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07379398) titled 'Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer' on Jan. 23.

Brief Summary: Major objectives to evaluate the efficacy and safety of lparomlimab and Tuvonralimab Injection ((QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)) combined with SBRT in patients with early-stage non-small cell lung cancer.

Study Start Date: April 01, 2026

Study Type: INTERVENTIONAL

Condition: NSCLC

Intervention: DRUG: lparomlimab and Tuvonralimab Injection in Combination with SBRT

lparomlimab and Tuvonralimab Injection: 5 mg/kg, administered every 3 weeks (q3w). The first dose should be g...